Kishore Jugal, Kumar Rohit, Nazli Tamanna, Ahmad Aftab, Kumar Pawan, Khan Asim A
Department of Community Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, IND.
Department of Pulmonary Critical Care and Sleep Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, IND.
Cureus. 2023 May 5;15(5):e38574. doi: 10.7759/cureus.38574. eCollection 2023 May.
Background The coronavirus disease 2019 (COVID-19) pandemic resulted in mortality and morbidity worldwide. Many treatment modalities have been experimented with limited success. Therefore, the traditional system of medicine needs to be explored. Objective To evaluate the benefits of Unani regimens and Unani Joshanda, as adjuvant therapy, were compared to standard treatment alone among reverse transcription polymerase chain reaction (RT-PCR)-confirmed mild to moderate COVID-19 cases. Materials and methods An open-label, double-arm, randomized, controlled interventional clinical study was conducted among 90 RT-PCR-confirmed mild to moderate COVID-19 inpatients admitted to a tertiary care hospital in New Delhi, India. Participants who fulfilled the criteria for inclusion were randomly assigned to two arms, with 43 subjects allocated to the Unani add-on arm and 47 subjects to the control arm receiving standard treatment alone. Results Clinical recovery was achieved in all patients of the Unani arm, while in the control arm, three (6.4%) patients deteriorated and had to be shifted to ICU following admission. In the intervention arm, a shorter duration of hospitalization was observed (mean 5.95 days {SD = 1.99}) than in the control arm (mean 7.62 days {SD, 4.06}); which was a statistically significant difference (p-value 0.017). The majority of the patients recovered within 10 days in the Unani add-on arm. The number of days taken for the reduction of symptoms was significantly less in the intervention arm (mean 5.14 days {SD, 2.39}) as compared with standard treatment (mean 6.53 days {SD, 3.06}) (p < 0.02). Renal and liver safety parameters were within the normal limits in both arms and no serious adverse event was reported. Conclusion Adding Unani formulations to standard treatment significantly reduced the duration of hospital stay and showed early recovery in COVID-19 patients compared with the control arm. It may be concluded that the synergistic effect of the Unani add-on with standard treatment gave more promising results in mild to moderate COVID-19 patients.
背景 2019 冠状病毒病（COVID-19）大流行在全球范围内导致了死亡和发病。许多治疗方式都进行了尝试，但成效有限。因此，需要探索传统医学体系。目的 评估尤纳尼疗法和尤纳尼乔山达（Unani Joshanda）作为辅助疗法，与单纯标准治疗相比，在逆转录聚合酶链反应（RT-PCR）确诊的轻至中度 COVID-19 病例中的益处。材料和方法 在印度新德里一家三级护理医院收治的 90 例 RT-PCR 确诊的轻至中度 COVID-19 住院患者中进行了一项开放标签、双臂、随机、对照干预性临床研究。符合纳入标准的参与者被随机分为两组，43 名受试者被分配到尤纳尼附加治疗组，47 名受试者被分配到仅接受标准治疗的对照组。结果 尤纳尼治疗组的所有患者均实现了临床康复，而对照组中有 3 名（6.4%）患者病情恶化，入院后不得不转至重症监护病房。在干预组中，观察到的住院时间（平均 5.95 天{标准差 = 1.99}）比对照组（平均 7.62 天{标准差，4.06}）短；这是一个具有统计学意义的差异（p 值 0.017）。在尤纳尼附加治疗组中，大多数患者在 10 天内康复。与标准治疗（平均 6.53 天{标准差，3.06}）相比，干预组症状减轻所需天数显著更少（平均 5.14 天{标准差，2.39}）（p < 0.02）。两组的肾脏和肝脏安全参数均在正常范围内，且未报告严重不良事件。结论 与对照组相比，在标准治疗中添加尤纳尼制剂显著缩短了 COVID-19 患者的住院时间，并显示出早期康复。可以得出结论，尤纳尼附加治疗与标准治疗的协同作用在轻至中度 COVID-19 患者中产生了更有前景的结果。
